Fast Track designation

Zepbound tirzepatide

Lilly's Zepbound homes in on potential FDA sleep apnea nod

After Novo's recent Wegovy approval to cut heart risks, Eli Lilly could be nearing the next potential label expansion for its rival weight loss med.

Fraiser Kansteiner Jun 24, 2024 10:33am

FDA

Biogen, Eisai kick off rolling FDA submission for subQ Leqembi

May 14, 2024 7:51pm

racecar

Lilly's tirzepatide fast-tracked by FDA in obesity

Oct 6, 2022 9:49am